“…Numerous studies have shown the potential of blood-based IMFs for the detection of cancer, notably brain ( Butler et al, 2019 ; Hands, 2014 ; Sala et al, 2020b ), breast ( Backhaus et al, 2010 ; Elmi et al, 2017 ; Ghimire et al, 2020 ; Zelig et al, 2015 ), bladder ( Ollesch et al, 2014 ), lung ( Ollesch et al, 2016 ), prostate ( Medipally et al, 2020 ), and other cancer entities ( Anderson et al, 2020 ; Ollesch et al, 2014 ; Sala et al, 2020a ), with some of the studies reporting specificities and sensitivities higher than 90% ( Anderson et al, 2020 ; Backhaus et al, 2010 ; Butler et al, 2019 ; Ghimire et al, 2020 ; Medipally et al, 2020 ; Ollesch et al, 2014 ). Despite these promising initial results, only a few studies involved more than 75 individuals per group ( Anderson et al, 2020 ). Additionally, the majority of these studies had a high risk of bias due to patient selection applied ( Anderson et al, 2020 ).…”